{
    "nct_id": "NCT04680052",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma",
    "inclusion_criteria": "* Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL\n* Willingness to avoid pregnancy or fathering children\n* In the opinion of the investigator, be able and willing to receive adequate mandatory prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or low-molecular-weight heparin)\n* Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy\n* Documented relapsed, refractory, or PD after treatment with systemic therapy\n* ECOG performance status of 0 to 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Women who are pregnant or breastfeeding.\n* Any histology other than FL and MZL or clinical evidence of transformed lymphoma\n* Prior non-hematologic malignancy\n* Congestive heart failure\n* HCV positivity, chronic HBV infection or history of HIV infection\n* Active systemic infection\n* CNS lymphoma involvement\n* Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of Cycle 1\n* Prior use of lenalidomide in combination with rituximab",
    "miscellaneous_criteria": ""
}